IQVIA is a global leader in the field of clinical research.
1/6
Asthma
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered at multiple dose levels over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.
2/6
Cardiovascular Diseases
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves disease-related biomarkers and slows the rate of progression of cognitive or clinical impairment.
3/6
Asthma
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered at multiple dose levels over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.
4/6
Cardiovascular Diseases
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves disease-related biomarkers and slows the rate of progression of cognitive or clinical impairment.
5/6
Cardiovascular Diseases
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves disease-related biomarkers and slows the rate of progression of cognitive or clinical impairment.
6/6
Cardiovascular Diseases
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves disease-related biomarkers and slows the rate of progression of cognitive or clinical impairment.
Understand Clinical Research1
Every new medication, treatment approach, preventive therapy, and medical device must undergo testing and evaluation before being approved for utilization as a standard of patient care. This is commonly known as the field of Clinical Research. Without the important work of clinical research professionals, the breakthrough findings of scientists would never translate into available treatments and quality of life benefits for patients.
Latest News
Alzheimer's Disease
How much do you know about Alzheimer's dementia?
Discover some common early symptoms and signs of Alzheimer's dementia
2023-01-30T18:30:00Z
Asthma
How much do you know about Alzheimer's dementia?
Discover some common early symptoms and signs of Alzheimer's dementia
2023-03-14T18:30:00Z
Asthma
How much do you know about Alzheimer's dementia?_Test_EE
Discover some common early symptoms and signs of Alzheimer's dementia
2023-03-14T18:30:00Z
Alzheimer's Disease
Stem cell research shows promise in treating relapsing-remitting multiple...
Pharmaceutical companies are rushing to fill the NASH treatment gap
2023-01-30T18:30:00Z
Nonalcoholic Steatohepatitis (NASH)
Making lifestyle changes: ten ideas to get started
Pharmaceutical companies are rushing to fill the NASH treatment gap
2023-03-14T18:30:00Z